A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)
A group of diseases arising from pregnancy that are commonly associated with hyperplasia of trophoblasts (TROPHOBLAST) and markedly elevated human CHORIONIC GONADOTROPIN. They include HYDATIDIFORM MOLE, invasive mole (HYDATIDIFORM MOLE, INVASIVE), placental-site trophoblastic tumor (TROPHOBLASTIC TUMOR, PLACENTAL SITE), and CHORIOCARCINOMA. These neoplasms have varying propensities for invasion and spread.
A malignant kidney tumor, caused by the uncontrolled multiplication of renal stem (blastemal), stromal (STROMAL CELLS), and epithelial (EPITHELIAL CELLS) elements. However, not all three are present in every case. Several genes or chromosomal areas have been associated with Wilms tumor which is usually found in childhood as a firm lump in a child's side or ABDOMEN.
Disordered formation of various types of leukocytes or an abnormal accumulation or deficiency of these cells.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)
Trophoblastic growth, which may be gestational or nongestational in origin. Trophoblastic neoplasia resulting from pregnancy is often described as gestational trophoblastic disease to distinguish it from germ cell tumors which frequently show trophoblastic elements, and from the trophoblastic differentiation which sometimes occurs in a wide variety of epithelial cancers. Gestational trophoblastic growth has several forms, including HYDATIDIFORM MOLE and CHORIOCARCINOMA. (From Holland et al., Cancer Medicine, 3d ed, p1691)
Administration of high doses of pharmaceuticals over short periods of time.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Tumors or cancers of the KIDNEY.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
Tumors or cancer located in bone tissue or specific BONES.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Services providing pharmaceutic and therapeutic drug information and consultation.
Prudent standard preventive measures to be taken by professional and other health personnel in contact with persons afflicted with a communicable disease, to avoid contracting the disease by contagion or infection. Precautions are especially applicable in the diagnosis and care of AIDS patients.
Organizations which provide an environment encouraging social interactions through group activities or individual relationships especially for the purpose of rehabilitating or supporting patients, individuals with common health problems, or the elderly. They include therapeutic social clubs.
The theory of the political, economic, and social equality of the sexes and organized activity on behalf of women's rights and interests. (Webster New Collegiate Dictionary, 1981)
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.
Personal names, given or surname, as cultural characteristics, as ethnological or religious patterns, as indications of the geographic distribution of families and inbreeding, etc. Analysis of isonymy, the quality of having the same or similar names, is useful in the study of population genetics. NAMES is used also for the history of names or name changes of corporate bodies, such as medical societies, universities, hospitals, government agencies, etc.
The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease.
Services offered to the library user. They include reference and circulation.
A form of RHABDOMYOSARCOMA arising primarily in the head and neck, especially the orbit, of children below the age of 10. The cells are smaller than those of other rhabdomyosarcomas and are of two basic cell types: spindle cells and round cells. This cancer is highly sensitive to chemotherapy and has a high cure rate with multi-modality therapy. (From Holland et al., Cancer Medicine, 3d ed, p2188)
A form of RHABDOMYOSARCOMA occurring mainly in adolescents and young adults, affecting muscles of the extremities, trunk, orbital region, etc. It is extremely malignant, metastasizing widely at an early stage. Few cures have been achieved and the prognosis is poor. "Alveolar" refers to its microscopic appearance simulating the cells of the respiratory alveolus. (Holland et al., Cancer Medicine, 3d ed, p2188)
A sex cord-gonadal stromal tumor consists of LEYDIG CELLS; SERTOLI CELLS; and FIBROBLASTS in varying proportions and degree of differentiation. Most such tumors produce ANDROGENS in the Leydig cells, formerly known as androblastoma or arrhenoblastoma. Androblastomas occur in the TESTIS or the OVARY causing precocious masculinization in the males, and defeminization, or virilization (VIRILISM) in the females. In some cases, the Sertoli cells produce ESTROGENS.
Trophoblastic hyperplasia associated with normal gestation, or molar pregnancy. It is characterized by the swelling of the CHORIONIC VILLI and elevated human CHORIONIC GONADOTROPIN. Hydatidiform moles or molar pregnancy may be categorized as complete or partial based on their gross morphology, histopathology, and karyotype.
Tumors or cancer of the UTERUS.
A malignant metastatic form of trophoblastic tumors. Unlike the HYDATIDIFORM MOLE, choriocarcinoma contains no CHORIONIC VILLI but rather sheets of undifferentiated cytotrophoblasts and syncytiotrophoblasts (TROPHOBLASTS). It is characterized by the large amounts of CHORIONIC GONADOTROPIN produced. Tissue origins can be determined by DNA analyses: placental (fetal) origin or non-placental origin (CHORIOCARCINOMA, NON-GESTATIONAL).
A malignant neoplasm of the lung composed chiefly or entirely of immature undifferentiated cells (i.e., blast forms) with little or virtually no stroma. (From Stedman, 25th ed)
The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
The salts or esters of salicylic acids, or salicylate esters of an organic acid. Some of these have analgesic, antipyretic, and anti-inflammatory activities by inhibiting prostaglandin synthesis.
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions.They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
2-Octylcyclopentaneheptanoic acids. The family of saturated carbon-20 cyclic fatty acids that represent the parent compounds of the prostaglandins.
Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.

Effect of hepatocarcinogens on the binding of glucocorticoid-receptor complex in rat liver nuclei. (1/3633)

The effects of a number of carcinogens and hepatotoxins on the binding kinetics of the interactions of glucocorticoidcytosol receptor complex with nuclear acceptor sites in rat liver were investigated. Both the apparent sites in rat liver were investigated. Both the apparent concentration of nuclear binding sites and the Kd were significantly diminished following treatment of rats with sublethal doses of the carcinogens aflatoxin B1, diethylnitrosamine, dimethylnitrosamine, thioacetamide, 3'-methyl-4-dimethylaminoazobenzene, 4-dimethylaminoazobenzene, and 3-methylcholanthrene. Treatment with actinomycin D resulted in a slight reduction in the apparent concentration of nuclear acceptor sites but had no effect on the nuclear binding Kd. The hepatotoxic but noncarcinogenic analgesic, acetaminophen, as well as the weakly toxic aflatoxin B1 cognate, aflatoxin B2, were without effect on the kinetics or binding capacity of glucocorticoid-nuclear acceptor site interaction. These experiments suggest that chemically induced alteration of functional glucocorticoid binding sites on chromatin may be involved in the biochemical effects produced in liver by carcinogens of several chemical types. This experimental model may provide a useful approach for further elucidation of early events in carcinogenesis.  (+info)

The stability and fate of a spliced intron from vertebrate cells. (2/3633)

Introns constitute most of the length of typical pre-mRNAs in vertebrate cells. Thus, the turnover rate of introns may significantly influence the availability of ribonucleotides and splicing factors for further rounds of transcription and RNA splicing, respectively. Given the importance of intron turnover, it is surprising that there have been no reports on the half-life of introns from higher eukaryotic cells. Here, we determined the stability of IVS1Cbeta1, the first intron from the constant region of the mouse T-cell receptor-beta, (TCR-beta) gene. Using a tetracycline (tet)-regulated promoter, we demonstrate that spliced IVS1Cbeta1 and its pre-mRNA had half-lives of 6.0+/-1.4 min and 3.7+/-1.0 min, respectively. We also examined the half-lives of these transcripts by using actinomycin D (Act.D). Act.D significantly stabilized IVS1Cbeta1 and its pre-mRNA, suggesting that Act.D not only blocks transcription but exerts rapid and direct posttranscriptional effects in the nucleus. We observed that in vivo spliced IVS1Cbeta1 accumulated predominantly as lariat molecules that use a consensus branchpoint nucleotide. The accumulation of IVS1Cbeta1 as a lariat did not result from an intrinsic inability to be debranched, as it could be debranched in vitro, albeit somewhat less efficiently than an adenovirus intron. Subcellular-fractionation and sucrose-gradient analyses showed that most spliced IVS1Cbeta1 lariats cofractionated with pre-mRNA, but not always with mRNA in the nucleus. Some IVS1Cbeta1 also appeared to be selectively exported to the cytoplasm, whereas TCR-beta pre-mRNA remained in the nucleus. This study constitutes the first detailed analysis of the stability and fate of a spliced nuclear intron in vivo.  (+info)

Retinoic acid stimulates the expression of 11beta-hydroxysteroid dehydrogenase type 2 in human choriocarcinoma JEG-3 cells. (3/3633)

The syncytiotrophoblasts of the human placenta express high levels of 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2), the enzyme responsible for the inactivation of glucocorticoids. It has been proposed that the placental 11beta-HSD2 serves as a barrier to protect the fetus from high levels of maternal cortisol. To examine the hypothesis that nutritional signals regulate the expression of 11beta-HSD2 in placental syncytiotrophoblasts, we investigated the effects of retinoic acids (RAs), the major metabolites of vitamin A, on the expression of 11beta-HSD2 using human choriocarcinoma JEG-3 cells as a model. This trophoblast-like cell line displays a number of functional similarities to the syncytiotrophoblast. Treatment for 24 h with all-trans RA (1-1000 nM) resulted in a dose-dependent increase in 11beta-HSD2 activity with a maximal effect (increase to 3-fold) at 100 nM. The effect of all-trans RA (100 nM) was also time-dependent in that the effect was detectable at 6 h and reached its maximum by 48 h. Similar increases in 11beta-HSD2 activity were observed when the cells were treated with 9-cis RA. Results from semi-quantitative reverse transcription-polymerase chain reaction demonstrated that there was a corresponding increase in 11beta-HSD2 mRNA after RA treatment. Moreover, treatment with actinomycin D (100 ng/ml) abrogated the increase in 11beta-HSD2 mRNA induced by RA, indicating an effect on transcription. In conclusion, the present study has demonstrated for the first time that RA, at physiological concentrations, induces 11beta-HSD2 gene expression and enzyme activity in JEG-3 cells. If this occurs in vivo, the present finding suggests that high expression of 11beta-HSD2 in the human placenta may be maintained, at least in part, by dietary intake of vitamin A.  (+info)

Inhibition of Pichinde virus replication by actinomycin D. (4/3633)

The yields of Pichinde virus, a member of the arenavirus group, were markedly inhibited when infected BHK 21 cells were incubated in the presence of 0.4 to 4 mug/ml of actinomycin D. Maximal inhibition was observed when actinomycin D was added after the adsorption of virus to cultures; however, addition of drug as late as 12 h after infection reduced the 24 h yield by 50%. Virus antigen synthesis, as measured by complement fixation and immunodiffusion, was not dramatically reduced by actinomycin D. The expression of virus antigens on the surface of infected cells was greater on cells treated with actinomycin D than on untreated cells. Putative defective particles with a density of Pichinde virus were not detected in fluids of cultures incubated with actinomycin D and 3H-amino acids. Actinomycin D appears to inhibit Pichinde virus late in the replicative cycle. The observations raise the possibility that the drug inhibits the synthesis of proteins of the host cell membrane which are required for virus maturation.  (+info)

Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma. (5/3633)

Oxygen deprivation is an important biological feature of tumor growth. We previously showed that in glioma, anoxia increases expression of IL-8, a chemokine and angiogenic factor. Here, we analysed for the first time the biochemical mechanisms inducing the IL-8 gene upon anoxia in glioma cells, and showed that they differ from those inducing the VEGF gene. Both genes are induced in biologically and genetically heterogenous glioblastoma cell lines (LN-229, LN-Z308, U87MG, T98G), whereas, in gliosarcoma cells (D247MG), only the VEGF gene is induced. The kinetics of IL-8 and VEGF mRNA inductions differ in these cells and reoxygenation experiments showed that the induction is due to the anoxic stress per se. Furthermore, in LN-229 and LN-Z308 cell lines actinomycin D, DRB and nuclear run-on experiments showed that anoxia stimulates increased transcription of both genes. Electromobility shift assays show increased protein binding to the AP-1 site on the IL-8 promoter following anoxia treatment. Finally, in situ hybridization on glioblastoma sections shows that the in vivo expression patterns of IL-8 and VEGF genes overlap, but are not identical. Since intratumoral augmentation of IL-8 and VEGF secretion, following microenvironmental decreases in oxygen pressure, may promote angiogenesis, further definition of these pathways is essential to appropriately target them for antitumoral therapy.  (+info)

Nuclear foci of mammalian recombination proteins are located at single-stranded DNA regions formed after DNA damage. (6/3633)

A sensitive and rapid in situ method was developed to visualize sites of single-stranded (ss) DNA in cultured cells and in experimental test animals. Anti-bromodeoxyuridine antibody recognizes the halogenated base analog incorporated into chromosomal DNA only when substituted DNA is in the single strand form. After treatment of cells with DNA-damaging agents or gamma irradiation, ssDNA molecules form nuclear foci in a dose-dependent manner within 60 min. The mammalian recombination protein Rad51 and the replication protein A then accumulate at sites of ssDNA and form foci, suggesting that these are sites of recombinational DNA repair.  (+info)

Interaction of asparagine and EGF in the regulation of ornithine decarboxylase in IEC-6 cells. (7/3633)

Our laboratory has shown that asparagine (ASN) stimulates both ornithine decarboxylase (ODC) activity and gene expression in an intestinal epithelial cell line (IEC-6). The effect of ASN is specific, and other A- and N-system amino acids are almost as effective as ASN when added alone. In the present study, epidermal growth factor (EGF) was unable to increase ODC activity in cells maintained in a salt-glucose solution (Earle's balanced salt solution). However, the addition of ASN (10 mM) in the presence of EGF (30 ng/ml) increased the activity of ODC 0.5- to 4-fold over that stimulated by ASN alone. EGF also showed induction of ODC with glutamine and alpha-aminoisobutyric acid, but ODC induction was maximum with ASN and EGF. Thus the mechanism of the interaction between ASN and EGF is important for understanding the regulation of ODC under physiological conditions. Therefore, we examined the expression of the ODC gene and those for several protooncogenes under the same conditions. Increased expression of the genes for c-Jun and c-Fos but not for ODC occurred with EGF alone. The addition of ASN did not further increase the expression of the protooncogenes, but the combination of EGF and ASN further increased the expression of ODC over that of ASN alone. Western analysis showed no significant difference in the level of ODC protein in Earle's balanced salt solution, ASN, EGF, or EGF plus ASN. Addition of cycloheximide during ASN and ASN plus EGF treatment completely inhibited ODC activity without affecting the level of ODC protein. These results indicated that 1) the increased expression of protooncogenes in response to EGF is independent of increases in ODC activity and 2) potentiation between EGF and ASN on ODC activity may not be due to increased gene transcription but to posttranslational regulation and the requirement of ongoing protein synthesis involving a specific factor dependent on ASN.  (+info)

Stochastic and nonstochastic post-transcriptional silencing of chitinase and beta-1,3-glucanase genes involves increased RNA turnover-possible role for ribosome-independent RNA degradation. (8/3633)

Stochastic and nonstochastic post-transcriptional gene silencing (PTGS) in Nicotiana sylvestris plants carrying tobacco class I chitinase (CHN) and beta-1,3-glucanase transgenes differs in incidence, stability, and pattern of expression. Measurements with inhibitors of RNA synthesis (cordycepin, actinomycin D, and alpha-amanitin) showed that both forms of PTGS are associated with increased sequence-specific degradation of transcripts, suggesting that increased RNA turnover may be a general feature of PTGS. The protein synthesis inhibitors cycloheximide and verrucarin A did not inhibit degradation of CHN RNA targeted for PTGS, confirming that PTGS-related RNA degradation does not depend on ongoing protein synthesis. Because verrucarin A, unlike cycloheximide, dissociates mRNA from ribosomes, our results also suggest that ribosome-associated RNA degradation pathways may not be involved in CHN PTGS.  (+info)

Dactinomycin 0.5mg Injection Exporter - Sarvajanik Pharmacy is a well known Exporter of Dactinomycin 0.5mg Injection, Dactinomycin 0.5mg Injection Exporter Mahesana, Dactinomycin 0.5mg Injection Export Company, Dactinomycin 0.5mg Injection Exporter from Gujarat India.
Dactinomycin is a cancer medication that interferes with the growth and spread of cancer cells in the body. Dactinomycin is used to treat different types of cancers that affect the kidneys, uterus, testicles, bones, muscles, joints, and soft tissues. Dactinomycin is also used to treat solid tumors. Dactinomycin may also...
Dactinomycin is an anti cancer drug. Dactinomycin is also a form of antibiotic which is useful in treating children related / pediatric forms of cancer.
Dactinomycin (Cosmegen, Actinomycin-D) chemotherapy side effects, how its given, how it works, precautions and self care tips for treatment of multiple cancers
MULTIPLE BINDING MODES OF ANTICANCER DRUG ACTINOMYCIN D: X-RAY, MOLECULAR MODELING, AND SPECTROSCOPIC STUDIES OF D(GAAGCTTC)2-ACTINOMYCIN D COMPLEXES AND ITS HOST ...
Your condition will be monitored carefully while you are receiving this medicine. You will need important blood work done while you are taking this medicine.. This drug may make you feel generally unwell. This is not uncommon, as chemotherapy can affect healthy cells as well as cancer cells. Report any side effects. Continue your course of treatment even though you feel ill unless your doctor tells you to stop.. Call your doctor or health care professional for advice if you get a fever, chills or sore throat, or other symptoms of a cold or flu. Do not treat yourself. This drug decreases your bodys ability to fight infections. Try to avoid being around people who are sick.. This medicine may increase your risk to bruise or bleed. Call your doctor or health care professional if you notice any unusual bleeding.. Talk to your doctor about your risk of cancer. You may be more at risk for certain types of cancers if you take this medicine.. Do not become pregnant while taking this medicine. Women ...
The optimal Hoechst dye concentration and staining time for different cell types vary as dye up-take depends on cellular metabolic rates; thus, both have to be determined empirically. In general, dye concentrations between 1mg/ml and 10 mg/ml and incubation times between 20 min and 90 min will produce DNA histograms with acceptable coefficients of variation. Because Hoechst DNA staining is performed on unfixed cells, it is possible to use other non-vital DNA dyes, e.g., PI, 7-aminoactinomycin D (7-AAD), for concurrent dead cell discrimination.. ...
Thymidine, a pyrimidine deoxynucleoside, is a DNA synthesis inhibitor that can arrest cell at G1/S boundary, prior to DNA replication. - Mechanism of Action & Protocol.
Dacilon information about active ingredients, pharmaceutical forms and doses by Celon Laboratories, Dacilon indications, usages and related health products lists
Mono- and Stereopictres of 5.0 Angstrom coordination sphere of Bromine atom in PDB 1unj: Crystal Structure of A 7-Aminoactinomycin D Complex With Non-Complementary Dna
The reconstruction of the nucleolus after mitosis was analyzed by electron microscopy in cultured mammalian (L929) cells in which nucleolar RNA synthesis was inhibited for a 3 h period either after or before mitosis. When synchronized mitotic cells were plated into a concentration of actinomycin D sufficient to block nucleolar RNA synthesis preferentially, nucleoli were formed at telophase as usual. 3 h after mitosis, these nucleoli had fibrillar and particulate components and possessed the segregated appearance characteristic of nucleoli of actinomycin D-treated cells. Cells in which actinomycin D was present for the last 3 h preceding mitosis did not form nucleoli by 3 h after mitosis though small fibrillar prenucleolar bodies were detectable at this time. These bodies subsequently grew in size and eventually acquired a particulate component. It took about a full cell cycle before nucleoli of these cells were completely normal in appearance. Thus, nucleolar RNA synthesis after mitosis is not ...
Actinomycin G (ActD), a good known transcription inhibitors, offers been widely reported to induce cell apoptosis in several types of growth cells by inhibiting the anti-apoptotic gene transcriptions. cell routine police arrest and apoptosis consequently. The present research possess exposed a book system by which ActD prevents osteosarcoma cell proliferations and induce apoptosis, and will offer an useful idea to chemotherapy in long term treatment of osteosarcoma. s using ANOVA testing for evaluations. The worth 0.05 (*), 0.01 (**) and 0.001 (***) was assumed as the level of significance for the figure testing carried out. Outcomes Actinomycin G prevents expansion of MG63 human being osteosarcoma cells Actinomycin G (ActD) can be reported to create anti-cancer activity by joining to guanine residues and suppressing DNA-dependent RNA polymerase [23]. Nevertheless, the toxic effects of ActD on osteosarcoma cells are not elucidated fully. To define the anti-cancer activity of ActD on osteosarcoma ...
Flt3 RGC-32 promoter activity. We previously reported that RGC-32 mRNA manifestation was considerably upregulated to 50-collapse within 24 h after TGF- induction of Monc-1 neural crest cells (21). To determine whether TGF- regulates RGC-32 gene transcription, we treated TGF-induced cells with transcription inhibitor actinomycin D. Actinomycin D abolished RGC-32 mRNA manifestation, recommending that TGF-induced response is definitely transcriptional (Fig. 1and performed an EMSA with nuclear components from Monc-1 cells treated with TGF- or automobile. We discovered that TGF- induced an discussion between nuclear elements and RGC-32 promoter as soon as 30 min following the induction (Fig. 2and and and and and and D). These data reveal that Smad2 rules of RGC-32 manifestation is an essential procedure in TGF-induced SMC differentiation of neural buy Faldaprevir crest cells. Fig. 7. Smad2 rules of RGC-32 can be very important to SMC marker gene manifestation. Control (shCtrl) or Smad2 shRNA ...
Chronic lymphocytic leukemia (CLL) is the most prevalent lymphoid malignancy in the elderly of the Western world. Although treatment options have improved over the past two decades, 10-15% of patients still have a poor prognosis and are often resistant to therapy. Aberrations in the p53 pathway, such as a deleted (del17p13) or mutated p53 gene, are highly enriched in this class of patients. In an extensive screen for p53-independent apoptosis inducers, actinomycin D was identified from 1496 substances and shown to induce apoptosis in primary CLL cells derived from high-risk patients including those with aberrant p53, revealing a novel p53-independent mechanism of action. Both pro-survival genes BCL2 and MCL1 are targeted by actinomycin D, in contrast to fludarabine the backbone of current treatment schedules. In the well-established TCL1 transgenic mouse model for high-risk CLL, actinomycin D treatment was more effective in reducing tumor load than fludarabine, with no evidence of resistance after three
Lists the various brand names available for medicines containing dactinomycin. Find information on dactinomycin use, treatment, drug class and molecular formula.
Buy Dacilon 0.5mg Online at low price in UK, Australia,China to treat Testicular cancer, Wilms tumor, Gestational trophoblastic neoplasia. This Injection contains Dactinomycin as active ingredient.
Perturbations in ribosome biogenesis or function, including those induced by oncogene activation, trigger a ribosomal stress response pathway mediated by ribosomal proteins (RP) such as RPL5 that modulate the function of the E3 ubiquitin ligase MDM2 and thus promote p53 stabilization and activity. Fregoso and colleagues found that the proto-oncogene serine/arginine-rich splicing factor 1 (SRSF1), which regulates multiple steps in gene expression in addition to splicing and is overexpressed in many cancers, specifically interacted with RPL5 and MDM2. This nuclear complex formed independently of mRNA or the ribosome and was distinct from the canonical RP-MDM2 complex. Actinomycin D-induced ribosomal stress enhanced this interaction and resulted in decreased ubiquitination and reduced degradation of p53 protein in the absence of changes in TP53 transcription, splicing, or mRNA stability and without augmenting p53 translation. Stabilization of p53 in response to ribosomal stress but not DNA damage ...
7-AAD (7-Aminoactinomycin D) is a nucleic acid dye that can be used to exclude nonviable cells from the analysis of flow cytometry data. |/p| |p||strong|Recent Publications:|/strong||br /| Kamachi F, Isshiki T, Harada N, Akiba H and Miyake S. 2015. Bi
7-AAD (7-Aminoactinomycin D) is a nucleic acid dye that can be used to exclude nonviable cells from the analysis of flow cytometry data. |/p| |p||strong|Recent Publications:|/strong||br /| Kamachi F, Isshiki T, Harada N, Akiba H and Miyake S. 2015. Bi
harvest pharmaceuticals inc. has prevailed an exclusive patent licensing patent agreement only with laboratoires tha blood of france for coiling of the us rights reduced to develop thought and equity market acetylsalicylic acid. The main effects each of acetylsalicylic acid at clinically relevant doses are mediated through inhibition respectively of nim
If you or someone close to you has been diagnosed with cancer, youre not alone. Find out what to expect, get information, practical advice and support, hear from experts and read about other peoples experiences.
Muscle, Skeletal;Muscle Proteins;Amino Acids;Amino Acids, Branched-Chain;Leucine;Lysine;Cycloheximide;Dactinomycin;Stimulation, Chemical;Tyrosine;Rats, ...
Nucelolar morphology was studied by electron microscopy in control and actinomycin D-treated populations of Tetrahymena pyriformis (W) during the cultural growth cycle. Nucleoli exhibit an aging cycle concomitant with the cultural growth cycle, but independent of the individual cell cycle. Four different stages in the course of this aging process have been defined. Stage 1 occurs upon inoculation (low number of cells per milliliter) and lasts through lag and accelerating growth phases. In this stage, many small nucleoli are found at the nuclear periphery. In stages 2 and 3, nucleolar fusion begins. Stage 2 dominates the first half of logarithmic growth, and stage 3 dominates the second half. In late decelerating growth phase, the nucleoli enter stage 4. In this stage, only a few large nucleoli are present and these are apparently inactive in ribosome production. In stationary phase, where total RNA remains constant, only stage 4 nucleoli are present. The relative preponderance of granular vs. ...
OUTLINE: Patients receive vincristine IV, dactinomycin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients then receive vincristine IV and dactinomycin IV on day 1. Treatment repeats every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.. PROJECTED ACCRUAL: A total of 41 patients will be accrued for this study. ...
PRIMARY OBJECTIVES:. I. Determine the failure-free survival of patients with newly diagnosed low-risk rhabdomyosarcoma treated with vincristine (V), dactinomycin (A), cyclophosphamide (C), and radiotherapy.. SECONDARY OBJECTIVES:. I. Determine local control rates in patients treated with this regimen. II. Determine the rate of second-look surgery in patients with bulk residual tumor at diagnosis (clinical group III) and the proportion of second-look surgeries that render patients treated with this regimen tumor-free or with microscopic tumor only and evaluate the pathologic significance of that residual tumor.. III. Determine the local control rates in patients with clinical group III disease treated with response-adjusted radiotherapy doses after second-look surgical resection.. OUTLINE: This is a nonrandomized, multicenter study. Patients are assigned to 1 of 2 treatment regimens according to disease stage and clinical group.. REGIMEN I (subset 1 patients) [closed to accrual as of 08/13/2010: ...
Bleomycin sulfate is a mixture of the sulfate salts of basic glycopeptide antineoplastic antibiotics isolated from Streptomyces verticillus.
Synthesis of a specific secretory protein was followed in the presence of actinomycin D and cordycepin (3-deoxyadenosine). The apparent half-life of the messenger RNA for this protein is significantly longer in the presence of actinomycin D than in the presence of cordycepin. These results suggest that actinomycin D studies of half-life in specialized cells may be inaccurate. ...
Mitomycin for injection by Hospira: Mitomycin belongs to the group of cancer-fighting medications known as antineoplastics, and specifically to the group of antineoplastics called actinomycins. Another actinomycin is dactinomycin.
I am interested in finding protocols for inhibiting protein and RNA synthesis in vivo in Arabidopsis. Specifically, I am interested in learning the appropritate concentrations of inhibitors such as, but not limited to, cyclohexamide and actinomycin D to use on intact plants, and the time it takes after treatment before one can expect to detect the inhibition. Also, I am interested in protocols that allow one to quantitate the effectiveness of the inhibitors, ie. how to use S35 Met and tritiated uracil to determine if the concentration of the inhibitors and the timing of the treatments were appropriate. Any information will be appreciated. Thanks. Dave Horvath MFT at CLVAX1.CL.MSU.EDU ...
Equal p110δ mRNA stability in leukocytes and non-leukocytes.The indicated cell lines were treated with Actinomycin D (4 µg/ml), an inhibitor of de novo RNA sy
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) ...
From the Lactobacillus family of organic bacteria, the microorganism acidophilus naturally occurs in the gut to aid the digestive system. Acidophilus bacterial cultures (also known as friendly bacteria) are an extra source of the micro-organisms that are naturally found throughout the digestive system. Acidophilus & Friendly Bacteria | Supplements | Vitamins & Supplements | Holland & Barrett
Tryptophan oxygenase (tryptophan 2,3-dioxygenase) activity increases immediately before the initiation of actinomycin D production by Streptomyces parvullus. We have attempted to discern whether this increase is due to a release from catabolite repression or to the synthesis of an inducer substance. The standard culture medium (glutamic acid-histidine-fructose medium) used in antibiotic production studies with S. parvullus contains l-glutamate as a major constituent. l-Glutamate is almost totally consumed before the onset of actinomycin D synthesis. The addition of 10 mM l-glutamate at this stage completely abolished actinomycin D production as well as tryptophan oxygenase synthesis. Fourteen amino acids were tested for a similar effect. Of these, l-glutamate and l-aspartate had the most dramatic effect on tryptophan oxygenase and beta-galactosidase (beta-d-galactosidase), another inducible enzyme. Standard glutamic acid-histidine-fructose medium, preincubated for 23 h to remove l-glutamate, allowed the
FIG. 1. Stability of PFR2 mRNA in promastigotes and amastigotes. Promastigotes and amastigotes were treated with actinomycin D (10 μg/ml) for the time indicated. Amastigotes received additional actinomycin D at 1 h. The zero time point was taken just prior to the addition of actinomycin D. Five micrograms of total RNA from each time point was fractionated, blotted, and probed with in vitro-synthesized RNA from pPFR2 as described in the text. (A) Representative Northern blots for the promastigote and amastigote time courses. The signals for the the PFR2 and rRNA probes are displayed. (B) PFR transcript abundance was quantitated by using a phosphorimager and was normalized to the small subunit of rRNA to control for loading. For each time point, the normalized values for PFR2 mRNA ([R]t) were divided by the normalized time zero value ([R]0) to obtain a value for the fraction of PFR2 mRNA remaining ([R]t/[R]0) which was plotted against time, in hours. The plotted data were fitted to the ...
RATIONALE: Drugs used in chemotherapy, such as vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop the growth of tumor cells
DNB Paper -1 Q-98 Healthy school environment constitutes all except: a. Per capita space in classroom should be 5 sq.ft. b. Minus desk be given c. One urinal for 60 students d. Window area should be 25% of floor space Ans-98 (a) Per capita space in classroom should be 5 sq.ft.,(b) Minus desk be given BONUS Q-107 Import General Manifest comes under? a. Customs act b. Railway act c. Transport act d. Merchant marine act DNB Paper-2 Q-61 Which of the following drug is contraindicated in hypertrophic cardiomyopathy : a. Digoxin b. Propranolol c. Verapamil d. Phenylephrine Ans61: (a) Digoxin Bonus Q-102 Life cycle inventory analysis based on? a. Criticality b. Low availability c. Consumption d. Emission into atmosphere Bonus Q-108Import General Manifest comes under? a. Customs act b. Railway act c. Transport act d. Merchant marine act ...
Kessel, D, Effects of camptothecin on rna synthesis in leukemia l1210 cells. (1971). Subject Strain Bibliography 1971. 891 ...
In this remarkably simple and profound article - recently appearing in the March issue of the Journal of Structural and Functional Genomics - Henry M.
Learn more about cycloheximide. We enable science by offering product choice, services, process excellence and our people make it happen.
Cerebellar granule cells are susceptible to the excitotoxin glutamate, which acts at N-methyl-D-aspartate (NMDA) receptors, as well as the neurotoxin 1-methyl-4-phenylpyridinium ion (MPP+), the active cytotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Paradoxically, preincubation of cultured cerebellar granule cells with low concentrations of NMDA or glutamate markedly antagonizes the neurotoxicity resulting from subsequent exposure to toxic concentrations of either MPP+ or glutamate. The neuroprotective effects of NMDA and glutamate against MPP+ toxicity are observed at agonist concentrations as low as 1 microM, are blocked by specific NMDA receptor antagonists, and require at least 30 min to develop fully. Moreover, NMDA receptor-mediated neuroprotection is prevented by the RNA synthesis inhibitor actinomycin D or the protein synthesis inhibitor cycloheximide. Thus, in cerebellar granule cells activation of NMDA receptors by glutamate can result in either ...
TY - JOUR AU - Grozdanović, Milica AU - Čavić, Milena AU - Nešić, Andrijana N. AU - Anđelković, Uroš AU - Akbari, Peyman AU - Smit, Joost J. AU - Gavrović-Jankulović, Marija PY - 2016 UR - http://cer.ihtm.bg.ac.rs/handle/123456789/3155 AB - Background: The intestinal epithelium forms a barrier that food allergens must cross in order to induce sensitization. The aim of this study was to evaluate the impact of the plant-derived food cysteine protease - actinidin (Act d1) on the integrity of intestinal epithelium tight junctions (TJs). Methods: Effects of Act d1 on the intestinal epithelium were evaluated in Caco-2 monolayers and in a mouse model by measuring transepithelial resistance and in vivo permeability. Integrity of the tight junctions was analyzed by confocal microscopy. Proteolysis of TJ protein occludin was evaluated by mass spectrometry. Results: Actinidin (1 mg/mL) reduced the transepithelial resistance of the cell monolayer by 18.1% (after 1 h) and 25.6% (after 4 h). This ...
BACKGROUND: The anti-HLA antibody can be detected using either a complement-dependent lymphocytotoxicity (CDC) assay or a flow cytometry crossmatch (FCXM) in renal transplantation. Discordant results are often obtained because the two methods detect different reaction phases between the donor lymphocytes and the recipient sera. This study was intended to confirm that antibody binding and cytotoxicity to the lymphocytes can be detected simultaneously in a single FCXM assay, cytotoxic FCXM.. METHODS: In the cytotoxic FCXM, the antibody binding to the lymphocytes was measured using anti-IgG-FITC, and the cytotoxicity using 7-aminoactinomycin D (7-AAD) after adding complement. For an evaluation of two test parameters, the cytotoxicity test moiety (dead-cell percentage) was compared with the anti-human globulin (AHG)-CDC, and the antibody-binding test moiety (sample/control fluorescence ratio) with the conventional FCXM in 77 positive and 30 negative crossmatches.. RESULTS: In the cytotoxic FCXM, ...
0112] A drug or active agent can include, but is not limited to, any substance capable of exerting a therapeutic, prophylactic, or diagnostic effect. The drugs for use in the implantable medical device, such as a stent or non-load bearing scaffolding structure may be of any or a combination of a therapeutic, prophylactic, or diagnostic agent. Examples of active agents include antiproliferative substances such as actinomycin D, or derivatives and analogs thereof (manufactured by Sigma-Aldrich 1001 West Saint Paul Avenue, Milwaukee, Wis. 53233; or COSMEGEN available from Merck). Synonyms of actinomycin D include dactinomycin, actinomycin IV, actinomycin I1, actinomycin X1, and actinomycin C1. The bioactive agent can also fall under the genus of antineoplastic, anti-inflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antiallergic and antioxidant substances. Examples of such antineoplastics and/or antimitotics include paclitaxel, (e.g., TAXOL® by ...
* found in: Biapenem, Astilbin, Allicin, aqueous solution, Aristolochic Acid B, Aflatoxin B2, Antimycin A, Aflatoxin M1, 7-Aminoactinomycin D, Aztreonam,..
Weigh out the appropriate amount of cycloheximide and add it to the appropriate amount of DMSO to get a 50mg/ml solution. Use the Botstein labs balance as it is much more accurate than ours. It seems to make the most sense to aim for about 100mg (but if it is slightly over or under that is fine) and then put this in a 2ml eppendorf or similar tube (you can use a 15ml conical if you are going to make a larger volume) and add the appropriate amount of DMSO to this based on what you weighed out. Cycloheximide is bad for you (see below) so be careful with it! ...
Robinson Cano and Damaso Marte both re-joined the Yankees today after returning from the World Baseball Classic. And both came back with injuries. Cano has...
An in vitro ischemia model was established and the effect of the metabolic inhibitors cycloheximide (CHX) and actinomycin D (ActD) on apoptosis in astrocytes under ischemia studied. CHX decreased by 75% the number of cells dying after 6 hr of ischemia compared with control cultures. TdT-mediated dUTP nick end labelling (TUNEL) staining of comparable cultures was reduced by 40%. ActD decreased cell death by 60% compared with controls. The number of TUNEL-positive cells was reduced by 38%. The nuclear shrinkage in TUNEL-positive astrocytes in control cultures did not occur in ActD-treated astrocytes, indicating that nuclear shrinkage and DNA fragmentation during apoptosis are two unrelated processes. Expression of bcl-2 (alpha and beta), bax, and Ice in astrocytes under similar ischemic conditions, as measured by quantitative reverse transcription-polymerase chain reaction, indicated that ischemia down-regulated bcl-2 (alpha and beta) and bax. Ice was initially down-regulated from 0 to 4 hr, ...
Introduction. The safety of generally recognized as safe food additives E407 and E407a is under rigorous debate. The aim of our research was to evaluate the effects of the orally administered food additive E407a (semi-refined carrageenan) on the viability of lymphocytes and their cell death modes. Methods. Totally, 16 adult WAG rats were divided into two equal groups (experimental - oral intake of 140 mg/kg of E407a during 2 weeks; control - oral consumption of drinking water instead). Blood samples were used to obtain leukocyte suspensions stained with Annexin V-FITC and 7-aminoactinomycin D (7-AAD). The region of lymphocytes was analyzed after collecting data using a BD FACSCanto™ II flow cytometer. Results. Oral administration of E407a led to a decrease in the amount of viable (Annexin V-, 7-AAD-) circulating lymphocytes. Furthermore, exposure to semi-refined carrageenan resulted in an elevated number of early apoptotic (Annexin V+, 7-AAD-) lymphocytes. Their percentage was approximately 4 times
Anthracyclines: Daunorubicin, Doxorubicin, Idarubicin, Valrubicin, Bleomycin Sulphate, Mitomycin-C : Dactinomycin or Actinomycin D, Plicamycin (Mithra
We have investigated the effect of chemotherapeutic and DNA damaging agents on binding of the tumor suppressor phosphoprotein p53 to its consensus DNA sequence. Activation of p53-DNA binding was seen for treatment with radiation, hydrogen peroxide, actinomycin D, Adriamycin, etoposide, camptothecin, 5-fluorouracil, mitomycin C, and cisplatin. These results showed that DNA strand breaks were sufficient to lead to increased levels of p53. The protein synthesis inhibitor cycloheximide blocks the increase in p53 following DNA damage. The increase in p53 activation in camptothecin treated cells may result, at least in part, from an increased half-life of the protein and consequent increases in intracellular protein concentration.. ...
Thank you for your interest in spreading the word about Science.. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.. ...
Et tu, Charlie Brown? Everything else is going 3-D and CG. Why not Lucy, Snoopy and the rest of the Peanuts gang? At least, that's what those behind a November 2015 release starring Charlie and his beloved canine are hoping. Directed by

No data available that match "dactinomycin"


Dactinomycin: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before receiving dactinomycin,. *tell your doctor and pharmacist if you are allergic to dactinomycin, any other medications, or ... Talk to your doctor about the risks of receiving dactinomycin injection.. Dactinomycin may cause other side effects. Call your ... If you become pregnant while receiving dactinomycin, call your doctor. Dactinomycin may harm the fetus. ...
Dactinomycin is a trade name for actinomycin D. It is a chemotherapy drug that is given as a treatment for some types of cancer ... Schwab M. (2015) Dactinomycin. In: Schwab M. (eds) Encyclopedia of Cancer. Springer, Berlin, Heidelberg. * .RIS Papers ... Dactinomycin is a trade name for actinomycin D. It is a chemotherapy drug that is given as a treatment for some types of cancer ...
Dactinomycin was approved for medical use in the United States in 1964. It is on the World Health Organizations List of ... Dactinomycin, also known as actinomycin D, is a chemotherapy medication used to treat a number of types of cancer. This ... Dactinomycin is in the cytotoxic antibiotic family of medications. It is believed to work by blocking the creation of RNA. ... "Dactinomycin". The American Society of Health-System Pharmacists. Archived from the original on 11 September 2017. Retrieved 8 ...
If you have an allergy to dactinomycin or any other part of this drug. ...
Dactinomycin (Cosmegen, Actinomycin-D) chemotherapy side effects, how its given, how it works, precautions and self care tips ... Dactinomycin is given through a vein (intravenous, IV) *Dactinomycin is classified as a vesicant medication, meaning it can ... Dactinomycin is the generic name for the trade name drug Cosmegen®. In some cases, health care professionals may use the trade ... Dactinomycin should not be given if you have or have been exposed to chicken pox or if you have recently had shingles. ...
If you or someone close to you has been diagnosed with cancer, youre not alone. Find out what to expect, get information, practical advice and support, hear from experts and read about other peoples experiences.
Find information on dactinomycin use, treatment, drug class and molecular formula. ... Lists the various brand names available for medicines containing dactinomycin. ... dactinomycin systemic. Brand names: Cosmegen. Drug class(es): antibiotics/antineoplastics. Dactinomycin systemic is used in the ... Dactinomycin. Important: The information below refers to products available in the United States that contain dactinomycin. ...
Harmonised classification and labelling is a legally binding classification and labelling for a substance, agreed at European Community level. Harmonisation is based on the substances physical, toxicological and eco-toxicological hazard assessment. The Hazard classification and labelling section uses the signal word, pictogram(s) and hazard statements of the substance under the harmonised classification and labelling (CLH) as its primary source of information.. If the substance is covered by more than one CLH entry (e.g. disodium tetraborate EC no. 215-540-4, is covered by three harmonisations: 005-011-00-4; 005-011-01-1 and 005-011-02-9), CLH information cannot be displayed in the InfoCard as the difference between the CLH classifications requires manual interpretation or verification. If a substance is classified under multiple CLH entries, a link to the C&L Inventory is provided to allow users to view CLH information associated with the substance and no text is automatically ...
As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations ... Dactinomycin. Injection, powder, for solution. 500 ug/1. Intravenous. Bedford Pharmaceuticals. 2010-07-12. 2012-05-31. US. ... Dactinomycin. Injection, powder, lyophilized, for solution. 0.5 mg/1mL. Intravenous. Mylan Institutional LLC. 2018-01-01. Not ... Dactinomycin. Injection, powder, lyophilized, for solution. 0.5 mg/1mL. Intravenous. Prasco, Laboratories. 2017-12-04. Not ...
Dactinomycin Lyophilisate for solution for injection drug summary. Find medication information including related drug classes, ... DACTINOMYCIN (dak ti noe MYE sin) is a chemotherapy drug. It is used to treat many kinds of cancer like Wilms tumor, some ... an unusual or allergic reaction to dactinomycin, other chemotherapy agents, other medicines, foods, dyes, or preservatives. - ...
Dactinomycin is also used to treat solid tumors. Dactinomycin may also... ... Dactinomycin is used to treat different types of cancers that affect the kidneys, uterus, testicles, bones, muscles, joints, ... Dactinomycin is a cancer medication that interferes with the growth and spread of cancer cells in the body. ... What is dactinomycin?. Dactinomycin is a cancer medication that interferes with the growth and spread of cancer cells in the ...
... and cyclophosphamide followed by vincristine and dactinomycin.. OUTLINE: Patients receive vincristine IV, dactinomycin IV, and ... Vincristine, Dactinomycin, and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma. The safety and scientific ... Drug Information available for: Cyclophosphamide Dactinomycin Vincristine sulfate Genetic and Rare Diseases Information Center ... Patients then receive vincristine IV and dactinomycin IV on day 1. Treatment repeats every 3 weeks for 8 courses in the absence ...
Blue Cross Blue Shield of Massachusetts is a leading provider of quality health insurance for residents of Massachusetts. Our main goal is to make health care cost-effective by offering health insurance solutions for individuals, families, and large and small businesses at affordable rates.. Our Vision - Making Quality Health Care ...
Dactinomycin, Actinomycin D injection. What is this medicine?. DACTINOMYCIN (dak ti noe MYE sin) is a chemotherapy drug. It is ... an unusual or allergic reaction to dactinomycin, other chemotherapy agents, other medicines, foods, dyes, or preservatives ...
Vincristine Dactinomycin and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma ... Vincristine Dactinomycin and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma Are you eligible to ...
... information about Abilify oral such as if you can you take Abilify oral when you are pregnant or nursing or If dactinomycin ... What should I Know Regarding Pregnancy, Nursing and Administering DACTINOMYCIN to Children or the Elderly? If you are PREGNANT ...
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia. The safety and scientific ... Biological: Dactinomycin Drug: Leucovorin Calcium Drug: Methotrexate Other: Quality-of-Life Assessment Phase 3 ... Drug Information available for: Dactinomycin Methotrexate Leucovorin calcium Genetic and Rare Diseases Information Center ... Dactinomycin. Levoleucovorin. Leucovorin. Bone Density Conservation Agents. Physiological Effects of Drugs. Abortifacient ...
Dactinomycin) is a significant polypeptide antibiotic isolated from soil bacteria of the genus Streptomyces. Actinomycin D ( ... Tags: buy Actinomycin D (Dactinomycin) , Actinomycin D (Dactinomycin) supplier , purchase Actinomycin D (Dactinomycin) , ... Actinomycin D (Dactinomycin) cost , Actinomycin D (Dactinomycin) manufacturer , order Actinomycin D (Dactinomycin) , ... Sellecks Actinomycin D (Dactinomycin) has been cited by 1 publication. * Nat Commun, 2018, 13;9(1):2720 PubMed: 30006524 ...
... dactinomycin, and cyclophosphamide, work in different ways to stop the growth of tumor cells ... dactinomycin, and cyclophosphamide followed by vincristine and dactinomycin.. OUTLINE: Patients receive vincristine IV, ... Patients then receive vincristine IV and dactinomycin IV on day 1.. Treatment repeats every 3 weeks for 8 courses in the ... dactinomycin IV, and cyclophosphamide IV on day 1.. Treatment repeats every 21 days for 8 courses in the absence of disease ...
Different effects of chloramphenicol, dactinomycin, and streptovitacin A on synthesis of tumor and virion antigens in SV40 ... Different effects of chloramphenicol, dactinomycin, and streptovitacin A on synthesis of tumor and virion antigens in SV40 ... Different effects of chloramphenicol, dactinomycin, and streptovitacin A on synthesis of tumor and virion antigens in SV40 ... Different effects of chloramphenicol, dactinomycin, and streptovitacin A on synthesis of tumor and virion antigens in SV40 ...
Vincristine Dactinomycin and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Embryonal ... dactinomycin, and cyclophosphamide with or without radiotherapy. OUTLINE: Patients receive vincristine IV, dactinomycin IV, and ... Vincristine Dactinomycin and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Embryonal ... RATIONALE: Drugs used in chemotherapy, such as vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop ...
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI ...
Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms tumor: ... Dactinomycin-induced Hepatic Sinusoidal Obstruction Syndrome Responding to Treatment with N-acetylcysteine Anselm Chi-wai Lee1 ... Dactinomycin-induced Hepatic Sinusoidal Obstruction Syndrome Responding to Treatment with N-acetylcysteine. J Cancer 2011; 2: ... Hepatic SOS typically appears after the second to sixth dose of dactinomycin, at seven to 14 days after the last dose [7]. ...
In polytheism the next phase of the experiment, linagliptin and dactinomycin were immediately given to the second younger ... Significantly better results have been obtained by giving local anesthesia injections of acetylsalicylic acid, dactinomycin and ...
Literature References: Antibiotic substance belonging to the actinomycin complex, produced by several Streptomyces spp. Historical background of actinomycins and chemistry, toxicology, pharmacology of actinomycin D: Ann. N.Y. Acad. Sci. 89, 285-485 (1960). Isoln from broth cultures of S. parvulus: Manaker et al., Antibiot. Ann. 1954/55, 853. Structure: Bullock, Johnson, J. Chem. Soc. 1957, 3280. Synthesis: Brockmann, Manegold, Naturwissenschaften 51, 383 (1964); Brockmann, Lackner, ibid. 384, 435 (1964); Brockmann et al., DE 1172680 (1964 to Bayer); eidem, Ber. 101, 1312 (1968); Meienhofer, J. Am. Chem. Soc. 92, 3771 (1970); T. Tanaka et al., Bull. Chem. Soc. Jpn. 53, 1352 (1980); K. Nakajima et al., Pept. Chem. 19, 143-148 (1981). Conformation from NMR: Conti, DeSantis, Nature 227, 1239 (1970); Lackner, Ber. 104, 3653 (1971). Toxicity data: F. S. Philips et al., Ann. N.Y. Acad. Sci. 89, 348 (1960). Review and evaluation of studies of carcinogenic action in laboratory animals: IARC Monographs ...
Description of the drug dactinomycin Intravenous. - patient information, description, dosage and directions. What is ... Uses For dactinomycin. Dactinomycin belongs to the group of medicines known as antineoplastics. It is used to treat some kinds ... After treatment with dactinomycin has ended, normal hair growth should return.. After you stop using dactinomycin, it may still ... Infection-Dactinomycin can decrease your bodys ability to fight infection. *Liver disease-Effects of dactinomycin may be ...
Dactinomycin, Actinomycin D injection. What is this medicine?. DACTINOMYCIN (dak ti noe MYE sin) is a chemotherapy drug. It is ... an unusual or allergic reaction to dactinomycin, other chemotherapy agents, other medicines, foods, dyes, or preservatives ...
... Helpful tips to write a good review:. * Only share your first hand experience as a consumer or a care ...
Source: Dactinomycin. View full report on Dactinomycin related vomiting Did the author experience vomiting while taking ... Dactinomycin Side Effects. Filter Table by Serious Outcome. ×. Filter by Serious Outcome. ... For more details, please use our Workbench for research on individual brands like Dactinomycin. ... The following are comments from users that experienced side effects while taking Dactinomycin ...
Dactinomycin (Cosmegen Lyovac ®). Daunorubicin De Gramont and modified de Gramont chemotherapy DHAP Chemotherapy ...
  • RATIONALE: Drugs used in chemotherapy, such as vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. (clinicaltrials.gov)
  • PURPOSE: This phase II trial is studying how well giving vincristine, dactinomycin, and cyclophosphamide together works in treating patients with embryonal rhabdomyosarcoma. (clinicaltrials.gov)
  • Determine the progression-free survival rate in patients with low-risk embryonal rhabdomyosarcoma treated with intensive chemotherapy comprising vincristine, dactinomycin, and cyclophosphamide followed by vincristine and dactinomycin. (clinicaltrials.gov)
  • OUTLINE: Patients receive vincristine IV, dactinomycin IV, and cyclophosphamide IV on day 1. (clinicaltrials.gov)
  • OBJECTIVES: - Determine the progression-free survival rate in patients with low-risk embryonal rhadomyosarcoma treated with a shortened treatment schedule of vincristine, dactinomycin, and cyclophosphamide with or without radiotherapy. (centerwatch.com)
  • Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease. (duke.edu)
  • OBJECTIVE: To evaluate the response rate and toxicity of alternating weekly therapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for women with high-risk gestational trophoblastic disease. (duke.edu)
  • CONCLUSION: The regimen of alternating weekly etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine is effective and well-tolerated chemotherapy for patients with high-risk gestational trophoblastic disease. (duke.edu)
  • Determine the toxic effects of this regimen when given in alternating courses with vincristine, dactinomycin, and cyclophosphamide (VAC) as continuation therapy in patients with partial or complete response. (bioportfolio.com)
  • This randomized phase III trial studies how well combination chemotherapy (vincristine sulfate, dactinomycin, cyclophosphamide) alternated with vincristine sulfate and irinotecan hydrochlo. (bioportfolio.com)
  • Your doctor will probably not want you to receive dactinomycin injection. (medlineplus.gov)
  • You should not receive dactinomycin if you have recently had chickenpox or herpes zoster (shingles). (wellspan.org)
  • You should not receive dactinomycin if you are allergic to it, or if you have recently had chickenpox or herpes zoster (shingles). (wellspan.org)
  • ARM I: Patients receive dactinomycin intravenously (IV) over 15 minutes on day 1. (clinicaltrials.gov)
  • Patients receive dactinomycin IV over 15 minutes on day 1. (clinicaltrials.gov)
  • What are the possible side effects of dactinomycin? (wellspan.org)
  • Before starting dactinomycin treatment, make sure you tell your doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc. (chemocare.com)
  • Dactinomycin is in the cytotoxic antibiotic family of medications. (wikipedia.org)
  • Dactinomycin is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. (chemocare.com)
  • Dactinomycin is believed to produce its cytotoxic effects by binding DNA and inhibiting RNA synthesis. (drugbank.ca)
  • Dactinomycin is a cytotoxic chemotherapy, prescribed for Wilm's tumor, Ewing s sarcoma and testicular cancer. (medindia.net)
  • Are you currently using dactinomycin vial? (webmd.com)
  • Each vial contains 0.5 mg (500 mcg) of dactinomycin and 20.0 mg of mannitol. (drugs.com)
  • A 16-month-old girl was receiving chemotherapy with vincristine and dactinomycin (Regimen EE-4A) for a left-sided Wilms tumor, clinicopathologic stage II with favorable histology, after nephrectomy. (jcancer.org)
  • To determine the two-year second event-free survival percentage for children who relapse following initial therapy with nephrectomy only following treatment with vincristine and dactinomycin, with or without doxorubicin, depending upon the site of relapse and presence or absence of microscopic residual disease. (clinicaltrials.gov)
  • Dactinomycin is an antineoplastic. (oncologydrugs.co.in)
  • According to the NCI dactinomycin is a chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces parvulus. (oncoletter.ch)
  • Dactinomycin is a type of antibiotic that is only used in cancer chemotherapy. (medlineplus.gov)
  • Actinomycin D (Dactinomycin) is a significant polypeptide antibiotic isolated from soil bacteria of the genus Streptomyces. (selleckchem.com)
  • Dactinomycin is also a form of antibiotic which is useful in treating children related / pediatric forms of cancer. (medicalrealm.net)
  • Dactinomycin is a cancer medication that interferes with the growth and spread of cancer cells in the body. (wellspan.org)
  • Dactinomycin interferes with the growth of cancer cells, which are eventually destroyed. (drugster.info)
  • Dactinomycin is also used alone or in combination with other medications to treat gestational trophoblastic tumors (a type of tumor that forms inside a woman's uterus while she is pregnant). (medlineplus.gov)
  • This randomized phase III trial studies how well methotrexate works compared to dactinomycin in treating patients with low-risk gestational trophoblastic neoplasia. (clinicaltrials.gov)
  • It is not yet known whether methotrexate is more effective than dactinomycin in treating gestational trophoblastic disease. (clinicaltrials.gov)
  • I. To test the hypothesis that treatment with multi-day methotrexate is inferior to treatment with pulse actinomycin-D (dactinomycin) in patients with low-risk gestational trophoblastic disease with respect to complete response. (clinicaltrials.gov)
  • Dactinomycin is used to treat Wilms' tumor, Childhood Rhabdomyosarcoma, Ovarian (germ cell) cancer, Gestational trophoblastic neoplasm, Ewing's sarcoma, Metastatic testicular tumors (nonseminoatous), Gestational trophoblastic neoplasm, Locally recurrent or locoregional solid tumors (sarcomas, carcinomas and adenocarcinomas), Soft tissue sarcoma and Osteosarcoma. (oddwayinternational.com)
  • Buy Dacilon Injection generic drug of Dactinomycin online at a low price from the most trusted pharmacy for Testicular cancer, Wilms' tumor, Gestational trophoblastic neoplasia. (safegenericpharmacy.net)
  • To evaluate the combination chemotherapy regimen with floxuridine , dactinomycin , etoposide , and vincristine (FAEV) as primary treatment for gestational trophoblastic neoplasia (GTN). (bvsalud.org)
  • The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to NanoSmart Pharmaceuticals' novel formulation of dactinomycin for the treatment of Ewing sarcoma, a rare type of childhood bone cancer. (ascopost.com)
  • The Food and Drug Administration (FDA) has granted Orphan Drug designation to dactinomycin nanoparticle formulation (NanoSmart) for the treatment of Ewing's sarcoma. (empr.com)
  • Dactinomycin is also used in combination with other medications to treat certain types of testicular cancer and Ewing's sarcoma (a type of cancer in bones or muscles). (medlineplus.gov)
  • Dactinomycin, also known as actinomycin D, is a chemotherapy medication used to treat a number of types of cancer. (wikipedia.org)
  • Dactinomycin is classified as a vesicant medication, meaning it can cause damage to tissue that comes in direct contact with the drug. (chemocare.com)
  • Dactinomycin may also be used for purposes not listed in this medication guide. (wellspan.org)
  • While treatment with antithrombotic or fibrinolytic agents and other agents has been attempted with variable success in hepatic SOS after stem cell transplantation [ 5 , 6 ], the efficacy of pharmacological intervention has not been systematically studied in dactinomycin-induced SOS. (jcancer.org)
  • Dactinomycin is used in combination with other medications, surgery, and/or radiation therapy to treat Wilms' tumor (a type of kidney cancer that occurs in children) and rhabdomyosarcoma (cancer that forms in muscles) in children. (medlineplus.gov)
  • Dactinomycin is a trade name for actinomycin D. It is a chemotherapy drug that is given as a treatment for some types of cancer, most commonly some cancers that occur in children such as Wilms' tumor and germ cell tumors, although it may sometimes be used for adults. (springer.com)
  • To make sure you can safely take dactinomycin, tell your doctor if you have recently received radiation treatment for Wilms tumor. (wellspan.org)
  • A 16-month-old girl with stage II Wilms tumor receiving post-nephrectomy chemotherapy with dactinomycin and vincristine developed hepatic sinusoidal obstruction syndrome with painful hepatomegaly, ascites with significant weight gain, grossly deranged liver function, severe thrombocytopenia, and reversal of blood flow in the portal vein on Doppler sonography. (jcancer.org)
  • stage I focal anaplastic (FA) or diffuse anaplastic (DA) Wilms' tumor: Patients receive regimen EE-4A comprising dactinomycin (DACT) IV weekly on weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate (VCR) IV weekly on weeks 1-10, 12, 15, and 18. (clinicaltrials.gov)
  • Because of increased toxicity, use of dactinomycin in infants less than 6 to 12 months of age is not recommended. (drugster.info)
  • However, the toxic properties of the actinomycins (including dactinomycin) in relation to antibacterial activity are such as to preclude their use as antibiotics in the treatment of infectious diseases. (drugbank.ca)
  • Dactinomycin is usually given only on certain days during a treatment cycle. (wellspan.org)
  • N-acetylcysteine is a safe and probably an effective treatment for dactinomycin-induced hepatic sinusoidal obstructive syndrome. (jcancer.org)
  • It is uncommon in the setting of conventional chemotherapy but tends to happen in children receiving dactinomycin treatment [ 3 , 4 ]. (jcancer.org)
  • Before you begin treatment with dactinomycin, you and your doctor should talk about the good dactinomycin will do as well as the risks of using it. (drugster.info)
  • Background: Dactinomycin (AMD) and vincristine (VCR) have been used for the treatment of childhood cancer over the past 40 years but evidence-based dosing guidance is lacking. (elsevier.com)
  • Dactinomycin may also be used to treat certain types of cancerous tumors that are located in a specific area of the body. (medlineplus.gov)
  • Dactinomycin is also used to treat solid tumors. (wellspan.org)
  • Dactinomycin belongs to the group of medicines known as antineoplastics. (drugster.info)
  • Patients then receive vincristine IV and dactinomycin IV on day 1. (clinicaltrials.gov)
  • Results of a study in patients with malignant melanoma indicate that dactinomycin ( 3 H actinomycin D) is minimally metabolized, is concentrated in nucleated cells, and does not penetrate the blood-brain barrier. (drugs.com)
  • Dactinomycin should be administered only into a vein. (medlineplus.gov)
  • Dactinomycin comes as a powder to be mixed with liquid to be injected intravenously (into a vein) by a doctor or nurse in a medical facility. (medlineplus.gov)
  • Dactinomycin is injected into a vein through an IV. (wellspan.org)
  • Actinomycin D (Dactinomycin) inhibits DNA repair and rests the cell cycle at G1 phase with IC50 of 0.42 μM and 0.4 nM, respectively. (selleckchem.com)
  • Pioneers in the industry, we offer pharmaceutical drop shipping, drop shipping service singapore post, clokeran 5mg (chlorambucil tablets), cytax 260 mg (paclitaxel injection), dacilon 0.5mg (dactinomycin injection) and epithra 100 mg (epirubicin injection) from India. (medicineonlineshop.com)
  • If you have an allergy to dactinomycin or any other part of this drug. (mskcc.org)
  • In some cases, health care professionals may use the trade name Cosmegen or other name Actinomycin-D when referring to the generic drug name dactinomycin. (chemocare.com)
  • DACTINOMYCIN (dak ti noe MYE sin) is a chemotherapy drug. (cvs.com)
  • Significantly better results have been obtained by giving local anesthesia injections of acetylsalicylic acid, dactinomycin and by chymotrypsin together than with by single drug alone. (todaysparentusa.com)
  • Dactinomycin is an anti cancer drug. (medicalrealm.net)
  • In polytheism the next phase of the experiment, linagliptin and dactinomycin were immediately given to the second younger generation mice after a training session. (todaysparentusa.com)
  • tell your doctor and pharmacist if you are allergic to dactinomycin, any other medications, or any of the ingredients in dactinomycin injection. (medlineplus.gov)
  • Tell your doctor if you have ever had any unusual or allergic reaction to dactinomycin or any other medicines. (drugster.info)
  • Dactinomycin injection must be given in a hospital or medical facility under the supervision of a doctor who is experienced in giving chemotherapy medications for cancer. (medlineplus.gov)
  • Dactinomycin is also sometimes used to treat a type of cancer of the ovaries (a cancer that begins in the female reproductive organs where eggs are formed). (medlineplus.gov)
  • The amount of dactinomycin that you will receive depends on many factors, including your height and weight, your general health or other health problems, and the type of cancer or condition being treated. (chemocare.com)
  • There is a slight risk of developing a secondary cancer months to years after taking dactinomycin. (chemocare.com)
  • Using dactinomycin may increase your risk of developing other types of cancer, such as leukemia. (wellspan.org)
  • Dactinomycin for injection should be administered only under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents. (drugster.info)
  • Dactinomycin may harm the fetus. (medlineplus.gov)
  • It is not known whether dactinomycin passes into breast milk or if it could harm a nursing baby. (wellspan.org)
  • Due to the toxic properties of dactinomycin (e.g., corrosivity, carcinogenicity, mutagenicity, teratogenicity), special handling procedures should be reviewed prior to handling and followed diligently. (drugster.info)
  • Using dactinomycin with any of the following medicines is not recommended. (drugster.info)
  • Dactinomycin side effects are often predictable in terms of their onset, duration and severity. (chemocare.com)
  • The risk or severity of bleeding can be increased when (R)-warfarin is combined with Dactinomycin. (drugbank.ca)
  • The risk or severity of adverse effects can be increased when Dactinomycin is combined with 2-Methoxyethanol. (drugbank.ca)
  • The risk or severity of adverse effects can be increased when Dactinomycin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. (drugbank.ca)
  • You should not become pregnant or breast-feed while you are receiving dactinomycin. (medlineplus.gov)
  • If you become pregnant while receiving dactinomycin, call your doctor. (medlineplus.gov)
  • Do not use dactinomycin if you are pregnant. (wellspan.org)

No images available that match "dactinomycin"